fbpx

Blog Page

Uncategorized

ONWARD Announces Completion of Enrollment in the Up-LIFT Pivotal Trial of ARC Therapy for Spinal Cord Injury – Yahoo Finance

Check back at 8:30 a.m. ET for results
Enrollment was completed in less than 12 months despite COVID-related challenges, demonstrating strong interest in the therapy
EINDHOVEN, the Netherlands & LAUSANNE, Switzerland, December 16, 2021–(BUSINESS WIRE)–
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014).
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, SOUTH-AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces it has completed enrollment in the Up-LIFT study, a pivotal trial to evaluate the safety and effectiveness of ARC Therapy to restore hand and arm function in people with spinal cord injury (SCI). Up-LIFT is the first large-scale pivotal trial of non-invasive spinal cord stimulation technology.
ONWARD has now reached the study’s enrollment ceiling of 65 subjects, enrolled at 14 leading SCI research sites throughout the United States, Canada, the United Kingdom, and the Netherlands. The Up-LIFT Study is a prospective, single-arm study designed to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation (ARC Therapy) to treat upper extremity functional deficits in people with chronic tetraplegia.
"The study reached its enrollment objective in under 12 months despite lock-downs, travel restrictions, and other COVID-related challenges," said Dave Marver, Chief Executive Officer of ONWARD. "This milestone underscores the SCI community’s enthusiasm for this promising therapy. We will now work with determination to prepare submissions to regulatory authorities in the US and Europe so we can bring this important therapy to market for the benefit of people with SCI and their loved ones."
"For individuals with impaired arm and hand function due to spinal cord injury, improved hand function directly translates into meaningful gains in terms of quality of life – being able to eat, dress or perform other daily life activities," said Edelle Field-Fote, PT, PhD, FAPTA, FASIA, co-PI of the Up-LIFT trial and Director of Spinal Cord Injury Research at Shepherd Center and Professor of Rehabilitation Medicine at Emory University School of Medicine. "It was very rewarding to take part in this important trial and collaborate with many of the most highly respected SCI rehabilitation centers across the globe."
"The end of enrollment for this trial marks a significant milestone in bringing non-invasive stimulation for restoring hand and arm function to people living with spinal cord injury" said Chet Moritz, PhD, co-PI of the Up-LIFT trial and Associate Professor in the Departments of Electrical & Computer Engineering and Rehabilitation Medicine at the University of Washington in Seattle. "We are hopeful this study can lead to the broad availability of this important therapy."
The company expects to initially commercialize ARC Therapy in the US, Germany, France, UK, Switzerland, and the Netherlands. To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com.
About ONWARD
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The company’s first FDA pivotal trial, called Up-LIFT, commenced in January 2021 and has now completed enrollment with 65 subjects worldwide.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office at the EPFL Innovation Park in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com.
About Dr. Edelle Field-Fote
Dr. Edelle Field-Fote has a 20+ years of SCI research, building on her clinical background as a physical therapist and Ph.D. training in an animal model of SCI. Her contributions to SCI literature include the largest study to date of locomotor training for persons with chronic, motor-incomplete SCI, as well as the first-ever study of a rehabilitation intervention to promote neuroplasticity for improved hand function in persons with tetraplegia. Dr. Field-Fote’s research has been funded by the National Institutes of Health (NIH) since 1997, and also by the National Institute on Independent Living, Disability and Rehabilitation Research (NILDRR) and the Department of Defense (DoD). Dr. Field-Fote is the editor/author of the textbook Spinal Cord Injury Rehabilitation (FA Davis Publishers).
About Dr. Chet Moritz
Dr. Chet Moritz is Associate Professor in the departments of Electrical & Computer Engineering, Rehabilitation Medicine, and Physiology & Biophysics at University of Washington, Seatlle. He was named an Allen Distinguished Investigator and appointed to the Christopher & Dana Reeve International Consortium on Spinal Cord Repair. Chet serves as the Co-Director for the Center for Neurotechnology, an NSF Engineering Research Center (ERC). Chet directs the Restorative Technologies Laboratory (RTL) which focuses on developing technologies to treat paralysis due to spinal cord injury. Current research in the lab includes a multi-site clinical trial of spinal stimulation to restore hand function for people with spinal cord injury, stimulation to improve walking for children with cerebral palsy, and optogenetic stimulation to guide neuroplasticity and recovery in the injured spinal cord of animals.
Disclaimer
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
50116485 M 33513785 / 1
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005922/en/
Contacts
For Company Enquiries:
ONWARD
info@onwd.com
For Media and Investor Enquiries:
Backstage Communication
Gunther De Backer
Tel: +32 (0)475 903 909
gunther@backstagecom.be
Inovio (INO) made a big splash last year with its Covid-19 DNA vaccine candidate INO-4800. Development, however, has been slow, and the vaccine is still a while away from entering the market, should it ever get that far. In the meantime, Inovio has been working on other, less headline grabbing candidates in its pipeline. On Tuesday, Inovio provided an update from the development of the Phase 3 program for VGX-3100, indicated to treat HPV-associated cervical high-grade squamous intraepithelial le
The pandemic has taken yet another turn with the discovery of the Omicron variant. Mounting research has shown that the latest version of the virus is likely to be more contagious and make currently available vaccines less effective. And as more information comes in, Anthony Fauci, MD, chief COVID adviser to the White House, is warning fully vaccinated people that there's still one major thing they need to do to protect themselves from the latest variant.RELATED: 70 Percent of Hospitalized Omicr
Is AbbVie stock a buy as shares retake their key moving averages on strong third-quarter earnings? Is ABBV stock a buy right now?
Investors are always on the lookout for untapped opportunities. Looking at the case for BioCryst Pharmaceuticals (BCRX), Oppenheimer’s Justin Kim thinks that the biotech fits the bill, calling it an “underappreciated commercial-stage company with pipeline growth potential.” At the heart of Kim’s thesis lies Orladeyo, the biotech’s treatment for the prevention of hereditary angioedema (HAE) attacks, which was granted FDA approval in December 2020. Characterized by unpredictable and possibly life-
Indonesian President Joko Widodo urged people and government officials to refrain from traveling abroad after the country detected its first case of the omicron variant of the coronavirus in a cleaning worker at a hospital in Jakarta. The patient has no symptoms and is being quarantined at the Athlete’s Village emergency hospital, where the person worked. Indonesia’s Health Minister Budi Gunadi Sadikin said the infection was confirmed on Wednesday, and he urged people to continue following recommended protocols, including wearing masks and maintaining physical distance.
The rapid spread of the omicron variant is the latest reminder that COVID-19 boosters may be necessary both now and in the future.
Omicron is triggering a “rather different” set of symptoms compared to previous variants, experts have warned, including lower back pain and a scratchy throat.
Stamford Health Director of Infectious Diseases Dr. Asha Shah joins Yahoo Finance Live to examine what experts know of the Omicron variant's transmissibility, also weighing in on how gatherings like professional sports events are being suspended and educators considering a return to at-home learning.
Is Pfizer stock a buy after a new Covid variant emerged that partially eludes protection from its Covid shot? Is PFE stock a buy right now?
(Bloomberg) — France is imposing tougher rules on people arriving from the U.K., including a requirement to self-isolate, to slow the spread of Covid-19’s omicron variant. The measures are introduced after new daily cases in the U.K. rose to a record. Most Read from BloombergCan Indoor Farms Reach Skyscraper Height?Saudi Arabia Wants Its Capital to Be Somewhere You’d Want to LiveZero Taxes, Golf and Beach Houses Create a Crypto Island ParadiseThe rise in infections is hitting economic activity
Shares of Eli Lilly (NYSE: LLY) were jumping 8.3% as of 11:48 a.m. ET on Wednesday. Lilly announced that it has initiated a rolling submission to the Food and Drug Administration for pirtobrutinib in treating mantle cell lymphoma. It also released new biomarker data showing positive efficacy for donanemab in treating Alzheimer's disease. Both ranges are well above consensus estimates.
A new private study by South Africa’s Discovery Health suggests that Pfizer Inc (NYSE: PFE) and BioNTech SE’s (NASDAQ: BNTX) COVID-19 vaccine is just 33% effective against infections by the omicron variant. However, the Company reported that the variant appears to cause less severe disease. Based on 211,000 positive COVID-19 cases, the data showed that the risk of hospitalization was 29% lower than in South Africa’s first wave back in mid-2020. The Pfizer/BioNTech shot was 70% effective at preve
The U.S. marked two grim milestones on Dec. 13 when it surpassed both the 50 million mark in all-time reported COVID-19 cases and 800,000 reported deaths since the beginning of the pandemic. Unfortunately, the national daily case average remains high after a month-long increase propelled it back to levels not seen since September. And over the weekend, experts pointed out that some states are seeing worse COVID surges than others as winter approaches and people gather indoors in increasing numbe
(Bloomberg) — For the past three years, Eli Lilly & Co. has been quietly watching and investing in technologies that harness the messaging power of cells in hopes that it could lead to new medicines.Most Read from BloombergCan Indoor Farms Reach Skyscraper Height?Zero Taxes, Golf and Beach Houses Create a Crypto Island ParadiseSaudi Arabia Wants Its Capital to Be Somewhere You’d Want to LiveChina Is Building the World’s Largest National Park SystemOne-fifth of the company’s pipeline is composed
WASHINGTON (Reuters) -A U.S. Centers for Disease Control and Prevention advisory panel will meet on Thursday to consider possible limits on the use of the Johnson & Johnson COVID-19 vaccine because of continued blood clot issues, the Washington Post reported on Wednesday. The CDC's Advisory Committee on Immunization Practices will be presented new data that appears to show the rate of clots in people who received the Johnson & Johnson vaccine has increased since April, the Post reported, citing clinicians familiar with the agenda. Use of the vaccine in the United States was paused for 10 days in April to investigate extremely rare but potentially deadly clots, mostly in young and middle-aged women.
The diesel fuel needed to produce oxygen for coronavirus patients has run out. This is the plight at the Afghan-Japan Hospital for communicable diseases, the only COVID-19 facility for the more than 4 million people who live in the capital of Kabul. While the coronavirus situation in Afghanistan appears to have improved from a few months ago when cases reached their peak, it is now the hospital itself that needs life support.
“We can save more lives with plant-based diet if people would only realize they are enslaved to fats, oil, sugar and things that are killing their body,” Adams said in a short 2018 film.
Nakia Hubbard Heard was pregnant with son, Saint, when she spent weeks hospitalized battling COVID-19. She continues to recover; Saint is healthy.
Americans feel ‘worn out’ by impact of virus in daily lives and changes they have had to make
In the short time since it was first identified, the Omicron variant has created concern among experts as it's managed to spread to dozens of countries. Officials in both the U.S. and Europe announced they expect the latest version of the virus to eclipse the Delta variant in dominance in the coming weeks. And now, new research shows that Omicron might affect how much the Pfizer vaccine protects someone from severe disease from the virus.RELATED: 70 Percent of Hospitalized Omicron Patients Have

source

× How can I help you?